When Mistakes Happen…
Medical error has been described as a public health emergency. Certainly, the numbers support this.
Opioid abuse – today’s exemplar of public health emergency – claimed an estimated 42,000 Americans in 2016, or about 115...
Online Exclusives
Lawsuit Asks FDA: “Where’s the Missing Data?”
A new lawsuit alleges that the U.S. Food and Drug Administration (FDA) is not holding clinical trial sponsors accountable for public reporting of clinical...
Politics in the Lab: Federal Officials Halt Research Using Fetal Tissue
The U.S. Department of Health and Human Services (HHS) is conducting an audit on federally funded research that uses fetal tissue. Several studies have...
News
From the Blood Journals
Preventing Hepatitis B Virus Reactivation During Immunochemotherapy for Lymphoma
Administering prophylactic antiviral treatment is effective in preventing hepatitis B virus (HBV) reactivation in patients with B-cell non-Hodgkin lymphoma (NHL) being treated with an...
Do Children With CVC-Related Thromboses Need Anticoagulation Treatment?
Results from a prospective study of children who were hospitalized in a pediatric intensive care unit (PICU) revealed that the incidence of central vein...
Multimedia
Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism
Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...
Ravulizumab: A New Treatment Option for PNH?
Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
A Rapid, Inexpensive Screening Test for Sickle Cell Disease in Uganda
Erik Serrao, PhD, discusses the HemoTypeSC test, which provides a rapid, cost-effective screening method for sickle cell disease in newborns living in limited-resource settings.
Elotuzumab Combination Prevents Progression from Smoldering to Symptomatic Myeloma
Irene Ghobrial, MD, shares results from a phase II trial, in which 84 percent of patients with high-risk smoldering multiple myeloma responded to treatment...
On Location
Ibrutinib Versus FCR: A “Paradigm Shift” for Younger Patients With Treatment-Naïve CLL
In patients with previously untreated chronic lymphocytic leukemia (CLL), treatment with an ibrutinib-based therapy improved...
Rivaroxaban Reduces Thrombotic Risk in Patients Undergoing Cancer Treatment
Primary prevention with the direct oral anticoagulant (DOAC) rivaroxaban reduced venous thromboembolism (VTE) and VTE-related...
New Tool Provides Simple Approach to Pausing Direct Oral Anticoagulants for Surgery
Researchers have developed a “simple, standardized, easy-to-use” strategy to guide decisions about interrupting direct oral...
Good News on the HORIZON: Melflufen Induces Response in Heavily Refractory Myeloma
One-third of patients with relapsed/refractory multiple myeloma (MM) that was refractory to pomalidomide and/or daratumumab...
For Older Patients With CLL, Ibrutinib Beats Standard Chemoimmunotherapy
Results from a randomized phase III study indicate that the Bruton tyrosine kinase (BTK) inhibitor...
Can Voxelotor Offer New HOPE for Sickle Cell Disease?
Treatment with voxelotor led to a dose-dependent increase in hemoglobin (Hb) levels in patients with...
Latest Headlines
ASH Directions
ASH Announces New Executive Committee Members, Hosts MDS+AML MATTER Education Program, and more
And The Winners Are …
ASH has announced the election of four new members to its Executive Committee for terms beginning after the 2018 ASH...
Nancy Berliner Named Next Editor-in-Chief of Blood, and more
ASH Launches New Sickle Cell Disease Clinical Trials Network
ASH has announced the launch of a clinical trials network in sickle cell disease (SCD) to...
ASH Presents Honorific Awards, Immunotherapy Researchers Receive Nobel Prize in Medicine, and more
American Society of Hematology Honors Distinguished Leaders at Annual Meeting
At its 60th annual meeting, the American Society of Hematology (ASH) will present several distinguished...
Lili Yang Wins $1.4 Million CIRM Quest Discovery Grant, and more
Remembering Thomas Michael Przybysz (1951-2018)
Thomas Michael Przybysz, MD, an oncologist, passed away on July 19, 2018, at the age of 66.
After serving in the...
Jonas Sokolof Named Director of NYU Langone’s New Rehab Program for Cancer Survivors, and...
Jonas Sokolof Appointed Director of NYU Langone’s New Rehabilitation Program for Cancer Survivors
NYU Langone’s Rusk Rehabilitation has opened the Division of Oncological Rehabilitation, launching...
When Mistakes Happen…
Medical error has been described as a public health emergency. Certainly, the numbers support this.
Opioid abuse – today’s exemplar of public health emergency –...
Progress Report: Is the Moonshot Mission on Schedule?
A little less than three years ago, former President Barack Obama called on then Vice President Joseph Biden to lead the new National Cancer...
Hazardous to Your Health: Violence in the Health-Care Workplace
The headline-making events are familiar and chilling: a Boston cardiologist murdered in a hospital by the son of a deceased patient; an Indiana physician...
